Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.94 USD
Change Today +0.04 / 2.11%
Volume 4.5M
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

cti biopharma corp (CTIC) Snapshot

Open
$1.88
Previous Close
$1.90
Day High
$1.94
Day Low
$1.86
52 Week High
06/10/14 - $3.23
52 Week Low
05/26/15 - $1.65
Market Cap
349.7M
Average Volume 10 Days
2.4M
EPS TTM
$-0.50
Shares Outstanding
180.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CTI BIOPHARMA CORP (CTIC)

Related News

No related news articles were found.

cti biopharma corp (CTIC) Related Businessweek News

No Related Businessweek News Found

cti biopharma corp (CTIC) Details

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral multikinase inhibitor with activity against Janus Kinase 2 and FMS-like tyrosine kinase, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II/III clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, including non-small cell lung, ovarian, breast, and prostate cancers. The company has development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA for the development and commercialization of pacritinib for use in oncology and other therapeutic areas. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

132 Employees
Last Reported Date: 03/12/15
Founded in 1991

cti biopharma corp (CTIC) Top Compensated Officers

Principal Founder, Chief Executive Officer, P...
Total Annual Compensation: $1.3M
Co-Founder, Principal Financial Officer, Prin...
Total Annual Compensation: $594.0K
Co-Founder, Chief Compliance Officer, Interim...
Total Annual Compensation: $545.8K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $544.4K
Compensation as of Fiscal Year 2014.

cti biopharma corp (CTIC) Key Developments

Cell Therapeutics Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Financial Guidance for 2015

Cell Therapeutics reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. The company posted mixed financial results for the first quarter, with a narrower-than-expected loss, and revenue in line with analysts' estimates. The company reported net loss of $28.6 million, or $0.16 per basic and diluted share, compared with the prior-year period's $29 million, or $0.20 loss per basic and diluted share. Revenue was $2.7 million, up from $1.4 million in the same quarter last year. Loss from operations was $27.483 million compared to $27.663 million a year ago. Adjusted loss from operations was $23.147 million compared to $19.834 million a year ago. The company also provided revenue guidance for fiscal 2015. The company reaffirms prior financial guidance that it expects total revenues for 2015 will be $50 million - $55 million, compared with the Street view is $60.4 million. It expects that non-GAAP operating loss for 2015 will be $75 million - $85 million, which excludes non-cash share-based compensation expense. These financial projections are primarily based on factors previously outlined in the company's fourth quarter and full year 2014 financial results press release.

CTI BioPharma Corp. to Report Q1, 2015 Results on May 06, 2015

CTI BioPharma Corp. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on May 06, 2015

CTI BioPharma Corp., Q1 2015 Earnings Call, May 06, 2015

CTI BioPharma Corp., Q1 2015 Earnings Call, May 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIC:US $1.94 USD +0.04

CTIC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Curis Inc $3.37 USD +0.12
Cytokinetics Inc $6.37 USD +0.11
Evotec AG €3.75 EUR -0.064
Progenics Pharmaceuticals Inc $5.63 USD +0.15
Rigel Pharmaceuticals Inc $3.49 USD +0.04
View Industry Companies
 

Industry Analysis

CTIC

Industry Average

Valuation CTIC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.4x
Price/Book 18.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CTI BIOPHARMA CORP, please visit www.ctibiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.